69 related articles for article (PubMed ID: 10389915)
1. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Minami H; Lad TE; Nicholas MK; Vokes EE; Ratain MJ
Clin Cancer Res; 1999 Jun; 5(6):1325-30. PubMed ID: 10389915
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
4. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
Pitot HC; Knost JA; Mahoney MR; Kugler J; Krook JE; Hatfield AK; Sargent DJ; Goldberg RM
Cancer; 2000 Oct; 89(8):1699-705. PubMed ID: 11042563
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
Leguizamo J; Quinn M; Takimoto CH; Liang MD; Ismail AS; Pang J; Dahut W; Grem JL
Cancer Chemother Pharmacol; 2003 Oct; 52(4):333-8. PubMed ID: 12819941
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
Dahut W; Harold N; Takimoto C; Allegra C; Chen A; Hamilton JM; Arbuck S; Sorensen M; Grollman F; Nakashima H; Lieberman R; Liang M; Corse W; Grem J
J Clin Oncol; 1996 Apr; 14(4):1236-44. PubMed ID: 8648379
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
[TBL] [Abstract][Full Text] [Related]
8. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
Thomas RR; Dahut W; Harold N; Grem JL; Monahan BP; Liang M; Band RA; Cottrell J; Llorens V; Smith JA; Corse W; Arbuck SG; Wright J; Chen AP; Shapiro JD; Hamilton JM; Allegra CJ; Takimoto CH
Cancer Chemother Pharmacol; 2001 Sep; 48(3):215-22. PubMed ID: 11592343
[TBL] [Abstract][Full Text] [Related]
10. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.
Takimoto CH; Dahut W; Marino MT; Nakashima H; Liang MD; Harold N; Lieberman R; Arbuck SG; Band RA; Chen AP; Hamilton JM; Cantilena LR; Allegra CJ; Grem JL
J Clin Oncol; 1997 Apr; 15(4):1492-501. PubMed ID: 9193345
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.
Sekine I; Nishiwaki Y; Watanabe K; Yoneda S; Saijo N
Clin Cancer Res; 1996 Jun; 2(6):941-5. PubMed ID: 9816254
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
[TBL] [Abstract][Full Text] [Related]
14. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
15. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.
Grossman SA; Hochberg F; Fisher J; Chen TL; Kim L; Gregory R; Grochow LB; Piantadosi S
Cancer Chemother Pharmacol; 1998; 42(2):118-26. PubMed ID: 9654111
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
17. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
[TBL] [Abstract][Full Text] [Related]
20. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]